Get access

Flt3 ligand does not differentiate between Parkinsonian disorders

Authors

  • Edina Silajdžić,

    Corresponding author
    1. Brain Disease Biomarker Unit, Department of Experimental Medical Science, Wallenberg Neuroscience Center, Lund University, Lund, Sweden
    • Correspondence to: Edina Silajdžić, Brain Disease Biomarker Unit, Department of Experimental Medical Science, Wallenberg Neuroscience Center, Lund University, SE-221 84, Lund, Sweden, E-mail: Edina.Silajdzic@med.lu.se

    Search for more papers by this author
  • Radu Constantinescu,

    1. Neurology Clinic, Sahlgrenska University Hospital, Gothenburg, Sweden
    Search for more papers by this author
  • Björn Holmberg,

    1. Neurology Clinic, Sahlgrenska University Hospital, Gothenburg, Sweden
    Search for more papers by this author
  • Maria Björkqvist,

    1. Brain Disease Biomarker Unit, Department of Experimental Medical Science, Wallenberg Neuroscience Center, Lund University, Lund, Sweden
    Search for more papers by this author
  • Oskar Hansson

    1. Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden
    2. Memory Clinic, Skåne University Hospital, Sweden
    Search for more papers by this author

  • Funding agencies: This study was supported by the Swedish Research Council and Parkinson Foundation in Sweden.

  • Relevant conflicts of interest/financial disclosures: Nothing to report.

  • Full financial disclosures and author roles may be found in the online version of this article.

Abstract

Background

Differential diagnosis of parkinsonian disorders is challenging because of overlapping symptoms, especially during early stages of disease. No validated biomarkers are available for early and accurate diagnosis of multiple system atrophy and other parkinsonian disorders. It has been reported that flt3 ligand levels in cerebrospinal fluid could clearly differentiate patients with Parkinson's disease from patients with multiple system atrophy, with 99% sensitivity and 95% specificity.

Methods

We measured flt3 ligand levels in cerebrospinal fluid of subjects with Parkinson's disease (n = 37), multiple system atrophy (n = 30), and progressive supranuclear palsy (n = 19).

Results

In our cohort, no significant difference was found in flt3 ligand levels between Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.

Conclusions

Our results suggest that cerebrospinal fluid flt3 ligand levels do not differentiate between parkinsonian disorders.

Get access to the full text of this article

Ancillary